AstraZeneca’s Dato-DXd shows ‘durable efficacy’ in HER2-low patients

Last night, the company announced: "Initial results from the TROPION-PanTumor01 Phase I trial of datopotamab deruxtecan, Dato-DXd, showed encouraging and durable efficacy in patients with heavily pretreated hormone receptor (HR)-positive, HER2-low or HER2-negative unresectable or metastatic breast cancer. Safety results were consistent with previous trials of datopotamab deruxtecan. Results were presented today at the 2022 San Antonio Breast Cancer Symposium. Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate being jointly developed by Daiichi Sankyo and AstraZeneca. In this cohort of TROPION-PanTumor01 (n=41), datopotamab deruxtecan demonstrated an objective response rate of 27% as assessed by blinded independent central review. All responses were partial and 56% of patients achieved stable disease. The disease control rate (DCR) was 85% and median progression-free survival was 8.3 months. With median follow-up of 13.7 months, the median duration of response and the median overall survival (OS) had not been reached with 59% of patients alive for more than one year." Reference Link